F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
The New York Times • • general
Key Points:
- The FDA has authorized early access to daraxonrasib, an experimental drug for patients with metastatic pancreatic cancer who have undergone prior treatment.
- Daraxonrasib, developed by Revolution Medicines, showed the most promising clinical trial results in pancreatic cancer to date but is not yet approved for general use.
- The expanded access program will allow some patients to receive the drug outside of clinical trials, where demand currently exceeds available slots.
- Pancreatic cancer has a very poor prognosis, with only 3% of patients with metastatic disease surviving five years post-diagnosis, and it accounts for about 8% of cancer deaths in the U.S. annually.
- It remains unclear how soon eligible patients can begin treatment under this new expanded access program.
